Lilly China deals, Akeso bispecific advance, ASCO updates reshape biotech
The Readout highlights Eli Lilly’s two China deals, Akeso’s promising lung cancer bispecific, and ASCO-driven updates on pancreatic cancer therapies (including daraxonrasib results), alongside chatter about a high-profile Chinese lung cancer therapy and a broader regulatory debate over an old peptide, illustrating how deals, trials, and policy are shaping biotech today.
